Why Glaxo should buy Biohaven
And four other potential targets that could make sense for the beleaguered group.
Glaxo needs long-acting HIV gamble to pay off
Dolutegravir’s patent expiry will pile on the pressure as Gilead and Merck get on the long-acting bandwagon.
New Glaxo: it’s all about the late-stage assets
Walmsley wins some breathing space but, for ambitious new growth targets to be met, the pipeline must start delivering.
Mitsubishi's Medicago readies for the second wave
Awaiting crucial pivotal data, company reckons its plant-generated Covid-19 vaccine can still make a contribution to the pandemic.
Astra and Sanofi’s RSV jab takes a step towards market
A pivotal win puts nirsevimab on track to be filed next year, but the reimbursement hurdle looms.
